- Home
- GWH vs GDTC Comparison
GWH vs GDTC Comparison
Compare GWH & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- GDTC
- Stock Information
- Founded
- GWH 2011
- GDTC 2018
- Country
- GWH United States
- GDTC Singapore
- Employees
- GWH N/A
- GDTC N/A
- Industry
- GWH Industrial Machinery/Components
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- GDTC Health Care
- Exchange
- GWH Nasdaq
- GDTC Nasdaq
- Market Cap
- GWH 29.3M
- GDTC 28.0M
- IPO Year
- GWH N/A
- GDTC 2023
- Fundamental
- Price
- GWH $2.15
- GDTC $2.40
- Analyst Decision
- GWH Hold
- GDTC Buy
- Analyst Count
- GWH 5
- GDTC 1
- Target Price
- GWH $2.10
- GDTC $5.00
- AVG Volume (30 Days)
- GWH 55.6K
- GDTC 32.5K
- Earning Date
- GWH 05-06-2025
- GDTC 01-01-0001
- Dividend Yield
- GWH N/A
- GDTC N/A
- EPS Growth
- GWH N/A
- GDTC N/A
- EPS
- GWH N/A
- GDTC N/A
- Revenue
- GWH $6,295,000.00
- GDTC $330,254.00
- Revenue This Year
- GWH $204.61
- GDTC $14.71
- Revenue Next Year
- GWH $159.83
- GDTC N/A
- P/E Ratio
- GWH N/A
- GDTC N/A
- Revenue Growth
- GWH N/A
- GDTC N/A
- 52 Week Low
- GWH $1.96
- GDTC $1.20
- 52 Week High
- GWH $14.10
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- GWH 33.97
- GDTC 48.41
- Support Level
- GWH $1.96
- GDTC $2.20
- Resistance Level
- GWH $2.74
- GDTC $2.46
- Average True Range (ATR)
- GWH 0.26
- GDTC 0.21
- MACD
- GWH 0.00
- GDTC 0.01
- Stochastic Oscillator
- GWH 24.36
- GDTC 34.67
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.